Barry Caldwell served as the President and CEO of Staar Surgical Company from November 2007 until his retirement in March 2015. His leadership was marked by his involvement in securing FDA approval for the company's ICLtm phakic implant, a significant...
Barry Caldwell served as the President and CEO of Staar Surgical Company from November 2007 until his retirement in March 2015. His leadership was marked by his involvement in securing FDA approval for the company's ICLtm phakic implant, a significant milestone for the business. In 2014, he decided to retire due to personal reasons, and after retirement, he continued on as a consultant until March 2016. He had a dynamic compensation structure during his time, with a peak salary of over $516,000 in 2014, but he did not earn a bonus that year as corporate goals weren’t met. Interestingly, during his tenure, he vested a substantial number of shares in restricted stock, including 45,000 shares worth approximately $669,000 in 2014 alone. Caldwell’s compensation package also included generous perks, such as relocation assistance and salary paid as stock, reflecting a strategic alignment with the company's growth. This combination of responsibilities and rewards showcases his long-term impact on the company’s direction and performance. He left a legacy of innovation and perseverance within Staar Surgical, laying the groundwork for its future success.